PS C:\Users\aritt\OneDrive\Desktop\PharmAI-Backend\app> Invoke-RestMethod -Uri "http://localhost:7860/run_stream" -Method POST -ContentType "application/json" -Body '{"session_id":"demo1","query":"Assess donanemab for early Alzheimer''s disease"}'
event: meta
data: {"session_id": "demo1", "has_prior_messages": false}

event: trace
data: {"raw": {"llm_call": {"messages": [{"content": [{"text": "I'll assess donanemab for early Alzheimer's disease. Let me gather the relevant information for you.\n\nFirst, let me extract the key entities from your query:", "type": "text"}, {"id": "toolu_018yFHQrgtoAhEsH3STDf6Ho", "input": {"query": "Assess donanemab for early Alzheimer's disease"}, "name": "extract_entities", "type": "tool_use"}], "additional_kwargs": {}, "response_metadata": {"id": "msg_017B4FiWWBnKiXWhTJynJbxa", "model": "claude-3-7-sonnet-20250219", "stop_reason": "tool_use", "stop_sequence": null, "usage": {"cache_creation": {"ephemeral_1h_input_tokens": 0, "ephemeral_5m_input_tokens": 0}, "cache_creation_input_tokens": 0, "cache_read_input_tokens": 0, "input_tokens": 1326, "output_tokens": 103, "server_tool_use": null, "service_tier": "standard"}, "model_name": "claude-3-7-sonnet-20250219", "model_provider": "anthropic"}, "type": "ai", "name": null, "id": "lc_run--019b2d12-e5a3-79d1-883c-8190c41ca8a5-0", "tool_calls": [{"name": "extract_entities", "args": {"query": "Assess donanemab for early Alzheimer's disease"}, "id": "toolu_018yFHQrgtoAhEsH3STDf6Ho", "type": "tool_call"}], "invalid_tool_calls": [], "usage_metadata": {"input_tokens": 1326, "output_tokens": 103, "total_tokens": 1429, "input_token_details": {"cache_read": 0, "cache_creation": 0, "ephemeral_5m_input_tokens": 0, "ephemeral_1h_input_tokens": 0}}}]}}}

event: message
data: {"node": "llm_call", "content": [{"text": "I'll assess donanemab for early Alzheimer's disease. Let me gather the relevant information for you.\n\nFirst, let me extract the key entities from your query:", "type": "text"}, {"id": "toolu_018yFHQrgtoAhEsH3STDf6Ho", "input": {"query": "Assess donanemab for early Alzheimer's disease"}, "name": "extract_entities", "type": "tool_use"}]}

event: trace
data: {"raw": {"tools": {"messages": [{"content": "{\"drug\": \"donanemab\", \"indication\": \"early Alzheimer's disease\"}", "additional_kwargs": {}, "response_metadata": {}, "type": "tool", "name": "extract_entities", "id": "b30b64d4-7df1-47bf-beb6-306d26d47d49", "tool_call_id": "toolu_018yFHQrgtoAhEsH3STDf6Ho", "artifact": null, "status": "success"}]}}}

event: message
data: {"node": "tools", "content": "{\"drug\": \"donanemab\", \"indication\": \"early Alzheimer's disease\"}"}

event: trace
data: {"raw": {"bump_tool_loop": {"tool_loops": 1}}}

event: trace
data: {"raw": {"llm_call": {"messages": [{"content": [{"text": "Now, I'll search for clinical trials information about donanemab for early Alzheimer's disease:", "type": "text"}, {"id": "toolu_017TwBKMHrxPRvnGuMVX92uz", "input": {"drug": "donanemab", "indication": "early Alzheimer's disease"}, "name": "clinicaltrials_search", "type": "tool_use"}], "additional_kwargs": {}, "response_metadata": {"id": "msg_016eNfH8ScctTbG8RiVuGLD6", "model": "claude-3-7-sonnet-20250219", "stop_reason": "tool_use", "stop_sequence": null, "usage": {"cache_creation": {"ephemeral_1h_input_tokens": 0, "ephemeral_5m_input_tokens": 0}, "cache_creation_input_tokens": 0, "cache_read_input_tokens": 0, "input_tokens": 1460, "output_tokens": 105, "server_tool_use": null, "service_tier": "standard"}, "model_name": "claude-3-7-sonnet-20250219", "model_provider": "anthropic"}, "type": "ai", "name": null, "id": "lc_run--019b2d12-f19d-7ba1-b64f-7fae26fc686e-0", "tool_calls": [{"name": "clinicaltrials_search", "args": {"drug": "donanemab", "indication": "early Alzheimer's disease"}, "id": "toolu_017TwBKMHrxPRvnGuMVX92uz", "type": "tool_call"}], "invalid_tool_calls": [], "usage_metadata": {"input_tokens": 1460, "output_tokens": 105, "total_tokens": 1565, "input_token_details": {"cache_read": 0, "cache_creation": 0, "ephemeral_5m_input_tokens": 0, "ephemeral_1h_input_tokens": 0}}}]}}}

event: message
data: {"node": "llm_call", "content": [{"text": "Now, I'll search for clinical trials information about donanemab for early Alzheimer's disease:", "type": "text"}, {"id": "toolu_017TwBKMHrxPRvnGuMVX92uz", "input": {"drug": "donanemab", "indication": "early Alzheimer's disease"}, "name": "clinicaltrials_search", "type": "tool_use"}]}

event: trace
data: {"raw": {"tools": {"messages": [{"content": "[{\"type\": \"clinical_trial\", \"source\": \"https://clinicaltrials.gov/study/NCT05508789\", \"summary\": \"The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including ...Read more\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://clinicaltrials.gov/study/NCT05508789\", \"title\": \"NCT05508789 | A Study of Donanemab (LY3002813) in ...\", \"content\": \"The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including ...Read more\", \"score\": 0.99995124, \"raw_content\": null}}, {\"type\": \"clinical_trial\", \"source\": \"https://www.clinicaltrials.gov/study/NCT04437511\", \"summary\": \"The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Read more\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.clinicaltrials.gov/study/NCT04437511\", \"title\": \"NCT04437511 | A Study of Donanemab (LY3002813) in ...\", \"content\": \"The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Read more\", \"score\": 0.99991107, \"raw_content\": null}}, {\"type\": \"clinical_trial\", \"source\": \"https://clinicaltrials.gov/study/NCT03367403\", \"summary\": \"Also called the NCT number, the format is \\\"NCT\\\" followed by an 8-digit ... Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18): ...Read more\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://clinicaltrials.gov/study/NCT03367403\", \"title\": \"NCT03367403 | A Study of LY3002813 in Participants With ...\", \"content\": \"Also called the NCT number, the format is \\\"NCT\\\" followed by an 8-digit ... Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18): ...Read more\", \"score\": 0.9997851, \"raw_content\": null}}, {\"type\": \"clinical_trial\", \"source\": \"https://clinicaltrials.gov/study/NCT05738486\", \"summary\": \"A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)(https://trials.lilly.com/en-US/trial ...Read more\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://clinicaltrials.gov/study/NCT05738486\", \"title\": \"NCT05738486 | A Study of Different Donanemab ...\", \"content\": \"A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)(https://trials.lilly.com/en-US/trial ...Read more\", \"score\": 0.99974483, \"raw_content\": null}}, {\"type\": \"clinical_trial\", \"source\": \"https://cdn.clinicaltrials.gov/large-docs/11/NCT04437511/Prot_000.pdf\", \"summary\": \"I5T-MC-AACI Protocol Amendment (e) Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease NCT04437511 Approval Date: 10-Nov-2022 CONFIDENTIAL I5T-MC-AACI(e) 1 Title Page Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. Protocol Title: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease Protocol Number: I5T-MC-\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://cdn.clinicaltrials.gov/large-docs/11/NCT04437511/Prot_000.pdf\", \"title\": \"Assessment of Safety, Tolerability, and Efficacy of ...\", \"content\": \"I5T-MC-AACI Protocol Amendment (e) Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease NCT04437511 Approval Date: 10-Nov-2022 CONFIDENTIAL I5T-MC-AACI(e) 1 Title Page Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. Protocol Title: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease Protocol Number: I5T-MC-AACI Amendment Number: e Compound: Donanemab (LY3002813) Study Phase: Phase 3 Short Title: Donanemab in Early Symptomatic Alzheimer’s Disease Acronym: TRAILBLAZER-ALZ 2 Sponsor Name: Eli Lilly and Company Legal Registered Address: Indianapolis, Indiana, USA 46285 Regulatory Agency Identifier Number(s): IND: 109157 EudraCT: 2020-000077-25 Approval Date: Protocol Amendment (e) Electronically Signed and Approved by Lilly on date provided below.\", \"score\": 0.99931216, \"raw_content\": null}}]", "additional_kwargs": {}, "response_metadata": {}, "type": "tool", "name": "clinicaltrials_search", "id": "7affee22-a504-4e06-b3fb-c5554db13092", "tool_call_id": "toolu_017TwBKMHrxPRvnGuMVX92uz", "artifact": null, "status": "success"}]}}}

event: message
data: {"node": "tools", "content": "[{\"type\": \"clinical_trial\", \"source\": \"https://clinicaltrials.gov/study/NCT05508789\", \"summary\": \"The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including ...Read more\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://clinicaltrials.gov/study/NCT05508789\", \"title\": \"NCT05508789 | A Study of Donanemab (LY3002813) in ...\", \"content\": \"The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including ...Read more\", \"score\": 0.99995124, \"raw_content\": null}}, {\"type\": \"clinical_trial\", \"source\": \"https://www.clinicaltrials.gov/study/NCT04437511\", \"summary\": \"The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Read more\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.clinicaltrials.gov/study/NCT04437511\", \"title\": \"NCT04437511 | A Study of Donanemab (LY3002813) in ...\", \"content\": \"The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Read more\", \"score\": 0.99991107, \"raw_content\": null}}, {\"type\": \"clinical_trial\", \"source\": \"https://clinicaltrials.gov/study/NCT03367403\", \"summary\": \"Also called the NCT number, the format is \\\"NCT\\\" followed by an 8-digit ... Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18): ...Read more\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://clinicaltrials.gov/study/NCT03367403\", \"title\": \"NCT03367403 | A Study of LY3002813 in Participants With ...\", \"content\": \"Also called the NCT number, the format is \\\"NCT\\\" followed by an 8-digit ... Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18): ...Read more\", \"score\": 0.9997851, \"raw_content\": null}}, {\"type\": \"clinical_trial\", \"source\": \"https://clinicaltrials.gov/study/NCT05738486\", \"summary\": \"A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)(https://trials.lilly.com/en-US/trial ...Read more\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://clinicaltrials.gov/study/NCT05738486\", \"title\": \"NCT05738486 | A Study of Different Donanemab ...\", \"content\": \"A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)(https://trials.lilly.com/en-US/trial ...Read more\", \"score\": 0.99974483, \"raw_content\": null}}, {\"type\": \"clinical_trial\", \"source\": \"https://cdn.clinicaltrials.gov/large-docs/11/NCT04437511/Prot_000.pdf\", \"summary\": \"I5T-MC-AACI Protocol Amendment (e) Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease NCT04437511 Approval Date: 10-Nov-2022 CONFIDENTIAL I5T-MC-AACI(e) 1 Title Page Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. Protocol Title: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease Protocol Number: I5T-MC-\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://cdn.clinicaltrials.gov/large-docs/11/NCT04437511/Prot_000.pdf\", \"title\": \"Assessment of Safety, Tolerability, and Efficacy of ...\", \"content\": \"I5T-MC-AACI Protocol Amendment (e) Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease NCT04437511 Approval Date: 10-Nov-2022 CONFIDENTIAL I5T-MC-AACI(e) 1 Title Page Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. Protocol Title: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease Protocol Number: I5T-MC-AACI Amendment Number: e Compound: Donanemab (LY3002813) Study Phase: Phase 3 Short Title: Donanemab in Early Symptomatic Alzheimer’s Disease Acronym: TRAILBLAZER-ALZ 2 Sponsor Name: Eli Lilly and Company Legal Registered Address: Indianapolis, Indiana, USA 46285 Regulatory Agency Identifier Number(s): IND: 109157 EudraCT: 2020-000077-25 Approval Date: Protocol Amendment (e) Electronically Signed and Approved by Lilly on date provided below.\", \"score\": 0.99931216, \"raw_content\": null}}]"}

event: trace
data: {"raw": {"bump_tool_loop": {"tool_loops": 2}}}

event: trace
data: {"raw": {"llm_call": {"messages": [{"content": [{"text": "Let me also search for more general information about donanemab for early Alzheimer's disease:", "type": "text"}, {"id": "toolu_01EL5DHbNHQ4Ecp7nDiDkFsW", "input": {"query": "donanemab FDA approval early Alzheimer's disease clinical trial results"}, "name": "web_search", "type": "tool_use"}], "additional_kwargs": {}, "response_metadata": {"id": "msg_01NDP1DTYUKcBvZfAsV1i5R9", "model": "claude-3-7-sonnet-20250219", "stop_reason": "tool_use", "stop_sequence": null, "usage": {"cache_creation": {"ephemeral_1h_input_tokens": 0, "ephemeral_5m_input_tokens": 0}, "cache_creation_input_tokens": 0, "cache_read_input_tokens": 0, "input_tokens": 2983, "output_tokens": 90, "server_tool_use": null, "service_tier": "standard"}, "model_name": "claude-3-7-sonnet-20250219", "model_provider": "anthropic"}, "type": "ai", "name": null, "id": "lc_run--019b2d13-0862-7f80-ab92-3002394072d3-0", "tool_calls": [{"name": "web_search", "args": {"query": "donanemab FDA approval early Alzheimer's disease clinical trial results"}, "id": "toolu_01EL5DHbNHQ4Ecp7nDiDkFsW", "type": "tool_call"}], "invalid_tool_calls": [], "usage_metadata": {"input_tokens": 2983, "output_tokens": 90, "total_tokens": 3073, "input_token_details": {"cache_read": 0, "cache_creation": 0, "ephemeral_5m_input_tokens": 0, "ephemeral_1h_input_tokens": 0}}}]}}}

event: message
data: {"node": "llm_call", "content": [{"text": "Let me also search for more general information about donanemab for early Alzheimer's disease:", "type": "text"}, {"id": "toolu_01EL5DHbNHQ4Ecp7nDiDkFsW", "input": {"query": "donanemab FDA approval early Alzheimer's disease clinical trial results"}, "name": "web_search", "type": "tool_use"}]}

event: trace
data: {"raw": {"tools": {"messages": [{"content": "[{\"type\": \"literature\", \"source\": \"https://clevelandadrc.org/education-resources/managing-dementia/new-information-regarding-an-fda-approved-treatment-for-alzheimers-disease/\", \"summary\": \"On July 2, the U.S. Food and Drug Administration (FDA) approved donanemab which has been developed by Eli Lilly and will be marketed under the name Kisunla™ for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease, with confirmed amyloid plaques. On January 6, 2023, the US Food and Drug Administration (FDA)  approved the anti-amyloid beta protofibril antibody lecanemab for the treatm\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://clevelandadrc.org/education-resources/managing-dementia/new-information-regarding-an-fda-approved-treatment-for-alzheimers-disease/\", \"title\": \"New information regarding FDA-approved treatments for Alzheimer's ...\", \"content\": \"On July 2, the U.S. Food and Drug Administration (FDA) approved donanemab which has been developed by Eli Lilly and will be marketed under the name Kisunla™ for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease, with confirmed amyloid plaques. On January 6, 2023, the US Food and Drug Administration (FDA)  approved the anti-amyloid beta protofibril antibody lecanemab for the treatment of patients with Alzheimer’s disease (AD). *There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.*  The FDA has approved lecanemab based upon results of the CLARITY AD clinical trial, which showed modest slowing of decline for patients with mild AD. In clinical trials, aducanumab, a medication that is given intravenously (IV) on an every 4 week basis, was tested with people in early stage of Alzheimer’s disease who were showing symptoms, such as memory loss, and who tested positive for amyloid plaques in the brain.\", \"score\": 0.9035075, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease\", \"summary\": \"The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials. The efficacy of Kisunla was evaluated in a double-blind, placebo-controlled, parallel-group study (Study 1, NCT04437511) in patients with Alzheimer’s disease. Patients treated with \", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease\", \"title\": \"FDA approves treatment for adults with Alzheimer's disease\", \"content\": \"The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials. The efficacy of Kisunla was evaluated in a double-blind, placebo-controlled, parallel-group study (Study 1, NCT04437511) in patients with Alzheimer’s disease. Patients treated with Kisunla demonstrated a statistically significant reduction in clinical decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) compared to placebo at Week 76 in the overall population (2.92, p<0.0001), as well as on the iADRS component scales, the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog13) (-1.33, p=0.0006) and the Alzheimer’s Disease Cooperative Study – instrumental Activities of Daily Living (ADCS-iADL) scale (1.70, p=0.0001). Patients treated with Kisunla also demonstrated a statistically significant reduction in clinical decline on the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) compared to placebo at Week 76 in the overall population (-0.70, p<0.0001).\", \"score\": 0.86358756, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://www.alzint.org/news-events/news/donanemab-update-new-alzheimers-disease-treatment-approved-by-the-fda/\", \"summary\": \"Eli Lilly presents results for Phase 2 TRAILBLAZER-ALZ trial for donanemab. Phase II trial results found that donanemab slowed cognitive and\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.alzint.org/news-events/news/donanemab-update-new-alzheimers-disease-treatment-approved-by-the-fda/\", \"title\": \"new Alzheimer's disease treatment approved by the FDA\", \"content\": \"Eli Lilly presents results for Phase 2 TRAILBLAZER-ALZ trial for donanemab. Phase II trial results found that donanemab slowed cognitive and\", \"score\": 0.85008353, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://www.nejm.org/doi/full/10.1056/NEJMoa2100708\", \"summary\": \"In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.nejm.org/doi/full/10.1056/NEJMoa2100708\", \"title\": \"Donanemab in Early Alzheimer's Disease | New England Journal of ...\", \"content\": \"In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform\", \"score\": 0.8338803, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://jamanetwork.com/journals/jama/fullarticle/2807533\", \"summary\": \"Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab treatment significantly slowed clinical progression at 76\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://jamanetwork.com/journals/jama/fullarticle/2807533\", \"title\": \"Trial of Donanemab in Early Symptomatic Alzheimer Disease\", \"content\": \"Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab treatment significantly slowed clinical progression at 76\", \"score\": 0.8194462, \"raw_content\": null}}]", "additional_kwargs": {}, "response_metadata": {}, "type": "tool", "name": "web_search", "id": "280b046b-bf5f-4dba-bb4e-9c3dbbc02e9e", "tool_call_id": "toolu_01EL5DHbNHQ4Ecp7nDiDkFsW", "artifact": null, "status": "success"}]}}}

event: message
data: {"node": "tools", "content": "[{\"type\": \"literature\", \"source\": \"https://clevelandadrc.org/education-resources/managing-dementia/new-information-regarding-an-fda-approved-treatment-for-alzheimers-disease/\", \"summary\": \"On July 2, the U.S. Food and Drug Administration (FDA) approved donanemab which has been developed by Eli Lilly and will be marketed under the name Kisunla™ for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease, with confirmed amyloid plaques. On January 6, 2023, the US Food and Drug Administration (FDA)  approved the anti-amyloid beta protofibril antibody lecanemab for the treatm\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://clevelandadrc.org/education-resources/managing-dementia/new-information-regarding-an-fda-approved-treatment-for-alzheimers-disease/\", \"title\": \"New information regarding FDA-approved treatments for Alzheimer's ...\", \"content\": \"On July 2, the U.S. Food and Drug Administration (FDA) approved donanemab which has been developed by Eli Lilly and will be marketed under the name Kisunla™ for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease, with confirmed amyloid plaques. On January 6, 2023, the US Food and Drug Administration (FDA)  approved the anti-amyloid beta protofibril antibody lecanemab for the treatment of patients with Alzheimer’s disease (AD). *There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.*  The FDA has approved lecanemab based upon results of the CLARITY AD clinical trial, which showed modest slowing of decline for patients with mild AD. In clinical trials, aducanumab, a medication that is given intravenously (IV) on an every 4 week basis, was tested with people in early stage of Alzheimer’s disease who were showing symptoms, such as memory loss, and who tested positive for amyloid plaques in the brain.\", \"score\": 0.9035075, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease\", \"summary\": \"The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials. The efficacy of Kisunla was evaluated in a double-blind, placebo-controlled, parallel-group study (Study 1, NCT04437511) in patients with Alzheimer’s disease. Patients treated with \", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease\", \"title\": \"FDA approves treatment for adults with Alzheimer's disease\", \"content\": \"The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials. The efficacy of Kisunla was evaluated in a double-blind, placebo-controlled, parallel-group study (Study 1, NCT04437511) in patients with Alzheimer’s disease. Patients treated with Kisunla demonstrated a statistically significant reduction in clinical decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) compared to placebo at Week 76 in the overall population (2.92, p<0.0001), as well as on the iADRS component scales, the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog13) (-1.33, p=0.0006) and the Alzheimer’s Disease Cooperative Study – instrumental Activities of Daily Living (ADCS-iADL) scale (1.70, p=0.0001). Patients treated with Kisunla also demonstrated a statistically significant reduction in clinical decline on the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) compared to placebo at Week 76 in the overall population (-0.70, p<0.0001).\", \"score\": 0.86358756, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://www.alzint.org/news-events/news/donanemab-update-new-alzheimers-disease-treatment-approved-by-the-fda/\", \"summary\": \"Eli Lilly presents results for Phase 2 TRAILBLAZER-ALZ trial for donanemab. Phase II trial results found that donanemab slowed cognitive and\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.alzint.org/news-events/news/donanemab-update-new-alzheimers-disease-treatment-approved-by-the-fda/\", \"title\": \"new Alzheimer's disease treatment approved by the FDA\", \"content\": \"Eli Lilly presents results for Phase 2 TRAILBLAZER-ALZ trial for donanemab. Phase II trial results found that donanemab slowed cognitive and\", \"score\": 0.85008353, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://www.nejm.org/doi/full/10.1056/NEJMoa2100708\", \"summary\": \"In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.nejm.org/doi/full/10.1056/NEJMoa2100708\", \"title\": \"Donanemab in Early Alzheimer's Disease | New England Journal of ...\", \"content\": \"In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform\", \"score\": 0.8338803, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://jamanetwork.com/journals/jama/fullarticle/2807533\", \"summary\": \"Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab treatment significantly slowed clinical progression at 76\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://jamanetwork.com/journals/jama/fullarticle/2807533\", \"title\": \"Trial of Donanemab in Early Symptomatic Alzheimer Disease\", \"content\": \"Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab treatment significantly slowed clinical progression at 76\", \"score\": 0.8194462, \"raw_content\": null}}]"}     

event: trace
data: {"raw": {"bump_tool_loop": {"tool_loops": 3}}}

event: trace
data: {"raw": {"llm_call": {"messages": [{"content": [{"text": "Let me search for more specific information about the efficacy and safety of donanemab:", "type": "text"}, {"id": "toolu_01Gswn485K77aRHZhM6eYFJx", "input": {"query": "donanemab efficacy safety ARIA side effects early Alzheimer's disease"}, "name": "web_search", "type": "tool_use"}], "additional_kwargs": {}, "response_metadata": {"id": "msg_019GvPQgqdM5KrnedkyPf9k6", "model": "claude-3-7-sonnet-20250219", "stop_reason": "tool_use", "stop_sequence": null, "usage": {"cache_creation": {"ephemeral_1h_input_tokens": 0, "ephemeral_5m_input_tokens": 0}, "cache_creation_input_tokens": 0, "cache_read_input_tokens": 0, "input_tokens": 4835, "output_tokens": 90, "server_tool_use": null, "service_tier": "standard"}, "model_name": "claude-3-7-sonnet-20250219", "model_provider": "anthropic"}, "type": "ai", "name": null, "id": "lc_run--019b2d13-1bd0-7f12-8442-8347c1f71c95-0", "tool_calls": [{"name": "web_search", "args": {"query": "donanemab efficacy safety ARIA side effects early Alzheimer's disease"}, "id": "toolu_01Gswn485K77aRHZhM6eYFJx", "type": "tool_call"}], "invalid_tool_calls": [], "usage_metadata": {"input_tokens": 4835, "output_tokens": 90, "total_tokens": 4925, "input_token_details": {"cache_read": 0, "cache_creation": 0, "ephemeral_5m_input_tokens": 0, "ephemeral_1h_input_tokens": 0}}}]}}}

event: message
data: {"node": "llm_call", "content": [{"text": "Let me search for more specific information about the efficacy and safety of donanemab:", "type": "text"}, {"id": "toolu_01Gswn485K77aRHZhM6eYFJx", "input": {"query": "donanemab efficacy safety ARIA side effects early Alzheimer's disease"}, "name": "web_search", "type": "tool_use"}]}

event: trace
data: {"raw": {"tools": {"messages": [{"content": "[{\"type\": \"literature\", \"source\": \"https://www.sciencedirect.com/science/article/pii/S2274580725000949\", \"summary\": \"Donanemab (Kisunla®), an IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β, is approved in the United States for treatment of early symptomatic Alzheimer's disease (AD). Appropriate Use Recommendations (AUR) were developed to guide the implementation of donanemab in real-world practice, prioritizing safety considerations and opportunity for effectiveness. Appropriate candidates for donanemab treatment include persons with mild cognitive impairment or mild de\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.sciencedirect.com/science/article/pii/S2274580725000949\", \"title\": \"Donanemab: Appropriate use recommendations - ScienceDirect.com\", \"content\": \"Donanemab (Kisunla®), an IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β, is approved in the United States for treatment of early symptomatic Alzheimer's disease (AD). Appropriate Use Recommendations (AUR) were developed to guide the implementation of donanemab in real-world practice, prioritizing safety considerations and opportunity for effectiveness. Appropriate candidates for donanemab treatment include persons with mild cognitive impairment or mild dementia due to AD (Clinical Stages 3–4, MMSE 20–30) who have biomarker confirmation of AD pathology by PET or CSF. Apolipoprotein E (*APOE*) genotyping should be performed prior to treatment to inform an individual's risk of developing Amyloid-Related Imaging Abnormalities (ARIA). Pre-treatment MRI should be obtained no more than 12 months prior to treatment. Patients with findings of >4 cerebral microbleeds, cortical superficial siderosis or a major vascular contribution to cognitive impairment should be excluded from treatment. Clinicians may consider discontinuing treatment if amyloid clearance is demonstrated by amyloid PET, typically obtained 12–18 months after initiating treatment.\", \"score\": 0.9999678, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC12040886/\", \"summary\": \"Inclusion criteria for this study were: 1) Published RCTs or clinical trials; 2) Participants were adults with early AD; 3) The intervention involved the use of Lecanemab or Donanemab in the experimental group and placebo in the control group, with treatment lasting at least 72 weeks; 4) Outcome measures included clinical outcomes (Clinical Dementia Rating Scale—Sum of Boxes (CDR-SB), Alzheimer’s Disease Assessment Scale (ADAS-Cog 14), Alzheimer’s Disease Composite Score (ADCOMS), and amyloid bu\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC12040886/\", \"title\": \"Re-evaluation of the efficacy and safety of anti-Aβ monoclonal ...\", \"content\": \"Inclusion criteria for this study were: 1) Published RCTs or clinical trials; 2) Participants were adults with early AD; 3) The intervention involved the use of Lecanemab or Donanemab in the experimental group and placebo in the control group, with treatment lasting at least 72 weeks; 4) Outcome measures included clinical outcomes (Clinical Dementia Rating Scale—Sum of Boxes (CDR-SB), Alzheimer’s Disease Assessment Scale (ADAS-Cog 14), Alzheimer’s Disease Composite Score (ADCOMS), and amyloid burden on PET), amyloid-related imaging abnormalities, and common adverse events (death, serious adverse events, falls, dizziness, headache, superficial siderosis of the central nervous system, arthralgia, urinary tract infection, diarrhea, anxiety). In summary, anti-Aβ monoclonal antibodies (Lecanemab/Donanemab) have demonstrated significant efficacy in improving cognitive function (as measured by the ADAS-Cog 14 scale) and activities of daily living (as assessed by the CDR-SB) in patients with early-stage Alzheimer’s disease, and have effectively reduced cerebral amyloid deposition (confirmed by PET imaging), thereby establishing their clinical value as disease-modifying treatments.\", \"score\": 0.99991906, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://dig.pharmacy.uic.edu/faqs/2024-2/sep-2024-faqs/what-evidence-supports-the-efficacy-and-safety-of-donanemab-for-alzheimer-disease/\", \"summary\": \"ARIA-E was observed in 24% of patients on donanemab vs 14% of patients on placebo · ARIA-H was observed in 31% of patients on donanemab vs 13% of\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://dig.pharmacy.uic.edu/faqs/2024-2/sep-2024-faqs/what-evidence-supports-the-efficacy-and-safety-of-donanemab-for-alzheimer-disease/\", \"title\": \"What evidence supports the efficacy and safety of donanemab for ...\", \"content\": \"ARIA-E was observed in 24% of patients on donanemab vs 14% of patients on placebo · ARIA-H was observed in 31% of patients on donanemab vs 13% of\", \"score\": 0.9998746, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://www.nejm.org/doi/full/10.1056/NEJMoa2100708\", \"summary\": \"In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.nejm.org/doi/full/10.1056/NEJMoa2100708\", \"title\": \"Donanemab in Early Alzheimer's Disease | New England Journal of ...\", \"content\": \"In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform\", \"score\": 0.99986756, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://www.neurologylive.com/view/donanemab-for-treatment-of-alzheimer-s-disease\", \"summary\": \"Efficacy: Donanemab significantly reduced amyloid plaque in treated patients, with rapid plaque removal seen within months of initiating therapy\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.neurologylive.com/view/donanemab-for-treatment-of-alzheimer-s-disease\", \"title\": \"Donanemab for Treatment of Alzheimer Disease - NeurologyLive\", \"content\": \"Efficacy: Donanemab significantly reduced amyloid plaque in treated patients, with rapid plaque removal seen within months of initiating therapy\", \"score\": 0.99984646, \"raw_content\": null}}]", "additional_kwargs": {}, "response_metadata": {}, "type": "tool", "name": "web_search", "id": "506607e8-ef7f-4b89-bc58-4e5f1de2248f", "tool_call_id": "toolu_01Gswn485K77aRHZhM6eYFJx", "artifact": null, "status": "success"}]}}}

event: message
data: {"node": "tools", "content": "[{\"type\": \"literature\", \"source\": \"https://www.sciencedirect.com/science/article/pii/S2274580725000949\", \"summary\": \"Donanemab (Kisunla®), an IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β, is approved in the United States for treatment of early symptomatic Alzheimer's disease (AD). Appropriate Use Recommendations (AUR) were developed to guide the implementation of donanemab in real-world practice, prioritizing safety considerations and opportunity for effectiveness. Appropriate candidates for donanemab treatment include persons with mild cognitive impairment or mild de\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.sciencedirect.com/science/article/pii/S2274580725000949\", \"title\": \"Donanemab: Appropriate use recommendations - ScienceDirect.com\", \"content\": \"Donanemab (Kisunla®), an IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β, is approved in the United States for treatment of early symptomatic Alzheimer's disease (AD). Appropriate Use Recommendations (AUR) were developed to guide the implementation of donanemab in real-world practice, prioritizing safety considerations and opportunity for effectiveness. Appropriate candidates for donanemab treatment include persons with mild cognitive impairment or mild dementia due to AD (Clinical Stages 3–4, MMSE 20–30) who have biomarker confirmation of AD pathology by PET or CSF. Apolipoprotein E (*APOE*) genotyping should be performed prior to treatment to inform an individual's risk of developing Amyloid-Related Imaging Abnormalities (ARIA). Pre-treatment MRI should be obtained no more than 12 months prior to treatment. Patients with findings of >4 cerebral microbleeds, cortical superficial siderosis or a major vascular contribution to cognitive impairment should be excluded from treatment. Clinicians may consider discontinuing treatment if amyloid clearance is demonstrated by amyloid PET, typically obtained 12–18 months after initiating treatment.\", \"score\": 0.9999678, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC12040886/\", \"summary\": \"Inclusion criteria for this study were: 1) Published RCTs or clinical trials; 2) Participants were adults with early AD; 3) The intervention involved the use of Lecanemab or Donanemab in the experimental group and placebo in the control group, with treatment lasting at least 72 weeks; 4) Outcome measures included clinical outcomes (Clinical Dementia Rating Scale—Sum of Boxes (CDR-SB), Alzheimer’s Disease Assessment Scale (ADAS-Cog 14), Alzheimer’s Disease Composite Score (ADCOMS), and amyloid bu\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC12040886/\", \"title\": \"Re-evaluation of the efficacy and safety of anti-Aβ monoclonal ...\", \"content\": \"Inclusion criteria for this study were: 1) Published RCTs or clinical trials; 2) Participants were adults with early AD; 3) The intervention involved the use of Lecanemab or Donanemab in the experimental group and placebo in the control group, with treatment lasting at least 72 weeks; 4) Outcome measures included clinical outcomes (Clinical Dementia Rating Scale—Sum of Boxes (CDR-SB), Alzheimer’s Disease Assessment Scale (ADAS-Cog 14), Alzheimer’s Disease Composite Score (ADCOMS), and amyloid burden on PET), amyloid-related imaging abnormalities, and common adverse events (death, serious adverse events, falls, dizziness, headache, superficial siderosis of the central nervous system, arthralgia, urinary tract infection, diarrhea, anxiety). In summary, anti-Aβ monoclonal antibodies (Lecanemab/Donanemab) have demonstrated significant efficacy in improving cognitive function (as measured by the ADAS-Cog 14 scale) and activities of daily living (as assessed by the CDR-SB) in patients with early-stage Alzheimer’s disease, and have effectively reduced cerebral amyloid deposition (confirmed by PET imaging), thereby establishing their clinical value as disease-modifying treatments.\", \"score\": 0.99991906, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://dig.pharmacy.uic.edu/faqs/2024-2/sep-2024-faqs/what-evidence-supports-the-efficacy-and-safety-of-donanemab-for-alzheimer-disease/\", \"summary\": \"ARIA-E was observed in 24% of patients on donanemab vs 14% of patients on placebo · ARIA-H was observed in 31% of patients on donanemab vs 13% of\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://dig.pharmacy.uic.edu/faqs/2024-2/sep-2024-faqs/what-evidence-supports-the-efficacy-and-safety-of-donanemab-for-alzheimer-disease/\", \"title\": \"What evidence supports the efficacy and safety of donanemab for ...\", \"content\": \"ARIA-E was observed in 24% of patients on donanemab vs 14% of patients on placebo · ARIA-H was observed in 31% of patients on donanemab vs 13% of\", \"score\": 0.9998746, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://www.nejm.org/doi/full/10.1056/NEJMoa2100708\", \"summary\": \"In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.nejm.org/doi/full/10.1056/NEJMoa2100708\", \"title\": \"Donanemab in Early Alzheimer's Disease | New England Journal of ...\", \"content\": \"In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform\", \"score\": 0.99986756, \"raw_content\": null}}, {\"type\": \"literature\", \"source\": \"https://www.neurologylive.com/view/donanemab-for-treatment-of-alzheimer-s-disease\", \"summary\": \"Efficacy: Donanemab significantly reduced amyloid plaque in treated patients, with rapid plaque removal seen within months of initiating therapy\", \"confidence\": 0.6, \"raw\": {\"url\": \"https://www.neurologylive.com/view/donanemab-for-treatment-of-alzheimer-s-disease\", \"title\": \"Donanemab for Treatment of Alzheimer Disease - NeurologyLive\", \"content\": \"Efficacy: Donanemab significantly reduced amyloid plaque in treated patients, with rapid plaque removal seen within months of initiating therapy\", \"score\": 0.99984646, \"raw_content\": null}}]"}

event: trace
data: {"raw": {"bump_tool_loop": {"tool_loops": 4}}}

event: trace
data: {"raw": {"llm_call": {"messages": [{"content": "# Donanemab Assessment for Early Alzheimer's Disease\n\n## Executive Summary\n\nDonanemab (marketed as Kisunla™) is an IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β. It received FDA approval on July 2, 2023, for the treatment of early symptomatic Alzheimer's disease, which includes mild cognitive impairment and mild dementia stages with confirmed amyloid plaques.\n\n## Regulatory Status\n\n- **FDA Approval**: Approved on July 2, 2023\n- **Indication**: Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)\n- **Requirements**: Patients must have confirmed amyloid plaques\n\n## Clinical Evidence\n\n### Key Clinical Trials\n\n1. **TRAILBLAZER-ALZ 2 (NCT04437511)** - Phase 3 pivotal trial\n   - Demonstrated statistically significant reduction in clinical decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) compared to placebo at Week 76\n   - Showed improvements on component scales:\n     - Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog13)\n     - Alzheimer's Disease Cooperative Study – instrumental Activities of Daily Living (ADCS-iADL)\n     - Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB)\n\n2. **TRAILBLAZER-ALZ (Phase 2)** - Earlier supportive trial\n   - Showed donanemab slowed cognitive and functional decline\n\n3. Other ongoing trials:\n   - NCT05508789 - Assessing safety and efficacy\n   - NCT05738486 (TRAILBLAZER-ALZ 6) - Evaluating different dosing regimens\n\n### Efficacy\n\n- Significantly slows clinical progression in early Alzheimer's disease patients with amyloid and tau pathology\n- Rapidly reduces amyloid plaque, with significant removal seen within months of initiating therapy\n- Improves composite scores for cognition and ability to perform daily activities\n\n## Safety Profile\n\n### ARIA (Amyloid-Related Imaging Abnormalities)\n\n- **ARIA-E** (edema): Observed in 24% of donanemab patients vs. 14% on placebo\n- **ARIA-H** (hemorrhage): Observed in 31% of donanemab patients vs. 13% on placebo\n\n### Risk Mitigation\n\n- APOE genotyping recommended prior to treatment to assess ARIA risk\n- Pre-treatment MRI should be obtained within 12 months before starting therapy\n- Exclusion criteria include:\n  - >4 cerebral microbleeds\n  - Cortical superficial siderosis\n  - Major vascular contribution to cognitive impairment\n\n## Patient Selection\n\nAppropriate candidates include:\n- Mild cognitive impairment or mild dementia due to AD (Clinical Stages 3–4, MMSE 20–30)\n- Biomarker confirmation of AD pathology by PET or CSF\n- No contraindications for ARIA risk\n\n## Treatment Considerations\n\n- Administered via intravenous injection\n- Treatment discontinuation may be considered if amyloid clearance is demonstrated by amyloid PET (typically 12-18 months after initiation)\n\n## Evidence Gaps\n\n1. **Long-term efficacy and safety**: Limited data beyond the duration of clinical trials\n2. **Real-world effectiveness**: Limited post-approval data in diverse populations\n3. **Comparative efficacy**: Direct comparisons with other approved anti-amyloid therapies (lecanemab, aducanumab) are lacking\n4. **Cost-effectiveness**: Economic analyses not fully established\n5. **Biomarker-guided treatment duration**: Optimal protocols for treatment discontinuation based on amyloid clearance\n6. **Patient-reported outcomes**: Limited data on quality of life measures\n7. **Specific dosing regimens**: Optimal dosing strategies still being investigated\n\n## Conclusion\n\nDonanemab represents a disease-modifying treatment for early Alzheimer's disease with demonstrated efficacy in slowing clinical progression and reducing amyloid plaque burden. However, treatment comes with significant ARIA risks that require careful patient selection and monitoring. The therapy is specifically indicated for early disease stages with confirmed amyloid pathology, highlighting the importance of appropriate diagnostic workup before initiation.", "additional_kwargs": {}, "response_metadata": {"id": "msg_01Doa5qWFGKu9PLLuYNpMUdE", "model": "claude-3-7-sonnet-20250219", "stop_reason": "end_turn", "stop_sequence": null, "usage": {"cache_creation": {"ephemeral_1h_input_tokens": 0, "ephemeral_5m_input_tokens": 0}, "cache_creation_input_tokens": 0, "cache_read_input_tokens": 0, "input_tokens": 6753, "output_tokens": 1028, "server_tool_use": null, "service_tier": "standard"}, "model_name": "claude-3-7-sonnet-20250219", "model_provider": "anthropic"}, "type": "ai", "name": null, "id": "lc_run--019b2d13-2c8f-7160-a4e1-ca17eb54b12a-0", "tool_calls": [], "invalid_tool_calls": [], "usage_metadata": {"input_tokens": 6753, "output_tokens": 1028, "total_tokens": 7781, "input_token_details": {"cache_read": 0, "cache_creation": 0, "ephemeral_5m_input_tokens": 0, "ephemeral_1h_input_tokens": 0}}}]}}}

event: message
data: {"node": "llm_call", "content": "# Donanemab Assessment for Early Alzheimer's Disease\n\n## Executive Summary\n\nDonanemab (marketed as Kisunla™) is an IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β. It received FDA approval on July 2, 2023, for the treatment of early symptomatic Alzheimer's disease, which includes mild cognitive impairment and mild dementia stages with confirmed amyloid plaques.\n\n## Regulatory Status\n\n- **FDA Approval**: Approved on July 2, 2023\n- **Indication**: Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)\n- **Requirements**: Patients must have confirmed amyloid plaques\n\n## Clinical Evidence\n\n### Key Clinical Trials\n\n1. **TRAILBLAZER-ALZ 2 (NCT04437511)** - Phase 3 pivotal trial\n   - Demonstrated statistically significant reduction in clinical decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) compared to placebo at Week 76\n   - Showed improvements on component scales:\n     - Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog13)\n     - Alzheimer's Disease Cooperative Study – instrumental Activities of Daily Living (ADCS-iADL)\n     - Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB)\n\n2. **TRAILBLAZER-ALZ (Phase 2)** - Earlier supportive trial\n   - Showed donanemab slowed cognitive and functional decline\n\n3. Other ongoing trials:\n   - NCT05508789 - Assessing safety and efficacy\n   - NCT05738486 (TRAILBLAZER-ALZ 6) - Evaluating different dosing regimens\n\n### Efficacy\n\n- Significantly slows clinical progression in early Alzheimer's disease patients with amyloid and tau pathology\n- Rapidly reduces amyloid plaque, with significant removal seen within months of initiating therapy\n- Improves composite scores for cognition and ability to perform daily activities\n\n## Safety Profile\n\n### ARIA (Amyloid-Related Imaging Abnormalities)\n\n- **ARIA-E** (edema): Observed in 24% of donanemab patients vs. 14% on placebo\n- **ARIA-H** (hemorrhage): Observed in 31% of donanemab patients vs. 13% on placebo\n\n### Risk Mitigation\n\n- APOE genotyping recommended prior to treatment to assess ARIA risk\n- Pre-treatment MRI should be obtained within 12 months before starting therapy\n- Exclusion criteria include:\n  - >4 cerebral microbleeds\n  - Cortical superficial siderosis\n  - Major vascular contribution to cognitive impairment\n\n## Patient Selection\n\nAppropriate candidates include:\n- Mild cognitive impairment or mild dementia due to AD (Clinical Stages 3–4, MMSE 20–30)\n- Biomarker confirmation of AD pathology by PET or CSF\n- No contraindications for ARIA risk\n\n## Treatment Considerations\n\n- Administered via intravenous injection\n- Treatment discontinuation may be considered if amyloid clearance is demonstrated by amyloid PET (typically 12-18 months after initiation)\n\n## Evidence Gaps\n\n1. **Long-term efficacy and safety**: Limited data beyond the duration of clinical trials\n2. **Real-world effectiveness**: Limited post-approval data in diverse populations\n3. **Comparative efficacy**: Direct comparisons with other approved anti-amyloid therapies (lecanemab, aducanumab) are lacking\n4. **Cost-effectiveness**: Economic analyses not fully established\n5. **Biomarker-guided treatment duration**: Optimal protocols for treatment discontinuation based on amyloid clearance\n6. **Patient-reported outcomes**: Limited data on quality of life measures\n7. **Specific dosing regimens**: Optimal dosing strategies still being investigated\n\n## Conclusion\n\nDonanemab represents a disease-modifying treatment for early Alzheimer's disease with demonstrated efficacy in slowing clinical progression and reducing amyloid plaque burden. However, treatment comes with significant ARIA risks that require careful patient selection and monitoring. The therapy is specifically indicated for early disease stages with confirmed amyloid pathology, highlighting the importance of appropriate diagnostic workup before initiation."}

event: trace
data: {"raw": {"synthesize": {"decision_brief": "# FINAL DECISION BRIEF: DONANEMAB FOR EARLY ALZHEIMER'S DISEASE\n\n## Executive Recommendation\nRecommend approval for donanemab (Kisunla™) for early Alzheimer's disease based on demonstrated efficacy in slowing clinical progression and favorable benefit-risk profile.\n\n## Scientific Rationale\n- IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β\n- Rapidly reduces amyloid plaque burden in the brain\n- Addresses a key pathological hallmark of Alzheimer's disease\n- Demonstrates disease-modifying potential by targeting underlying pathology\n\n## Clinical Evidence Snapshot\n- FDA approved on July 2, 2023 for early symptomatic Alzheimer's disease\n- TRAILBLAZER-ALZ 2 (Phase 3) showed statistically significant reduction in clinical decline at Week 76\n- Demonstrated improvements on iADRS, ADAS-Cog13, ADCS-iADL, and CDR-SB scales\n- 24% of patients experienced ARIA-E vs. 14% on placebo\n- 31% of patients experienced ARIA-H vs. 13% on placebo\n- Rapid amyloid plaque clearance observed within months of treatment initiation\n- Treatment discontinuation possible after amyloid clearance (typically 12-18 months)\n\n## IP / Exclusivity Quick View\n- Developed by Eli Lilly and Company\n- Marketed under brand name Kisunla™\n- Recent FDA approval (July 2023) suggests strong patent protection remaining\n- Biologics typically receive 12 years of exclusivity from approval date\n\n## Market / SoC Snapshot\n- Joins lecanemab (Leqembi) and aducanumab (Aduhelm) as FDA-approved anti-amyloid antibodies\n- Addresses large and growing patient population with early Alzheimer's disease\n- Requires specialized infrastructure for administration and monitoring\n- Potential market differentiation through rapid plaque clearance and treatment discontinuation protocol\n- Requires biomarker confirmation of amyloid pathology prior to treatment\n- APOE genotyping recommended for risk stratification\n\n## Key Risks + Next Actions\n- ARIA risk requires careful patient selection and monitoring protocols\n- Need for MRI monitoring increases healthcare resource utilization\n- Specialized infusion centers and trained personnel required\n- Establish clear protocols for patient selection, monitoring, and treatment discontinuation\n- Develop risk mitigation strategies for ARIA management\n- Implement education programs for healthcare providers and patients\n- Consider real-world evidence collection to assess long-term outcomes\n\n## Evidence Gaps\n- Limited data on long-term efficacy beyond clinical trial duration\n- Lack of direct comparative studies with other anti-amyloid therapies\n- Insufficient data on quality of life and patient-reported outcomes\n- Limited evidence on cost-effectiveness and healthcare resource utilization\n- Optimal treatment duration and discontinuation criteria not fully established\n- Real-world effectiveness in diverse populations not yet demonstrated\n\n## Citations\n1. https://clinicaltrials.gov/study/NCT05508789\n2. https://www.clinicaltrials.gov/study/NCT04437511\n3. https://clinicaltrials.gov/study/NCT03367403\n4. https://clinicaltrials.gov/study/NCT05738486\n5. https://cdn.clinicaltrials.gov/large-docs/11/NCT04437511/Prot_000.pdf\n6. https://trials.lilly.com/en-US/trial\n7. https://clevelandadrc.org/education-resources/managing-dementia/new-information-regarding-an-fda-approved-treatment-for-alzheimers-disease/\n8. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease\n9. https://www.alzint.org/news-events/news/donanemab-update-new-alzheimers-disease-treatment-approved-by-the-fda/\n10. https://www.nejm.org/doi/full/10.1056/NEJMoa2100708\n11. https://jamanetwork.com/journals/jama/fullarticle/2807533\n12. https://www.sciencedirect.com/science/article/pii/S2274580725000949\n13. https://pmc.ncbi.nlm.nih.gov/articles/PMC12040886/\n14. https://dig.pharmacy.uic.edu/faqs/2024-2/sep-2024-faqs/what-evidence-supports-the-efficacy-and-safety-of-donanemab-for-alzheimer-disease/\n15. https://www.neurologylive.com/view/donanemab-for-treatment-of-alzheimer-s-disease", "citations": ["https://clinicaltrials.gov/study/NCT05508789", "https://www.clinicaltrials.gov/study/NCT04437511", "https://clinicaltrials.gov/study/NCT03367403", "https://clinicaltrials.gov/study/NCT05738486", "https://cdn.clinicaltrials.gov/large-docs/11/NCT04437511/Prot_000.pdf", "https://trials.lilly.com/en-US/trial", "https://clevelandadrc.org/education-resources/managing-dementia/new-information-regarding-an-fda-approved-treatment-for-alzheimers-disease/", "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease", "https://www.alzint.org/news-events/news/donanemab-update-new-alzheimers-disease-treatment-approved-by-the-fda/", "https://www.nejm.org/doi/full/10.1056/NEJMoa2100708", "https://jamanetwork.com/journals/jama/fullarticle/2807533", "https://www.sciencedirect.com/science/article/pii/S2274580725000949", "https://pmc.ncbi.nlm.nih.gov/articles/PMC12040886/", "https://dig.pharmacy.uic.edu/faqs/2024-2/sep-2024-faqs/what-evidence-supports-the-efficacy-and-safety-of-donanemab-for-alzheimer-disease/", "https://www.neurologylive.com/view/donanemab-for-treatment-of-alzheimer-s-disease"], "messages": [{"content": "# FINAL DECISION BRIEF: DONANEMAB FOR EARLY ALZHEIMER'S DISEASE\n\n## Executive Recommendation\nRecommend approval for donanemab (Kisunla™) for early Alzheimer's disease based on demonstrated efficacy in slowing clinical progression and favorable benefit-risk profile.\n\n## Scientific Rationale\n- IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β\n- Rapidly reduces amyloid plaque burden in the brain\n- Addresses a key pathological hallmark of Alzheimer's disease\n- Demonstrates disease-modifying potential by targeting underlying pathology\n\n## Clinical Evidence Snapshot\n- FDA approved on July 2, 2023 for early symptomatic Alzheimer's disease\n- TRAILBLAZER-ALZ 2 (Phase 3) showed statistically significant reduction in clinical decline at Week 76\n- Demonstrated improvements on iADRS, ADAS-Cog13, ADCS-iADL, and CDR-SB scales\n- 24% of patients experienced ARIA-E vs. 14% on placebo\n- 31% of patients experienced ARIA-H vs. 13% on placebo\n- Rapid amyloid plaque clearance observed within months of treatment initiation\n- Treatment discontinuation possible after amyloid clearance (typically 12-18 months)\n\n## IP / Exclusivity Quick View\n- Developed by Eli Lilly and Company\n- Marketed under brand name Kisunla™\n- Recent FDA approval (July 2023) suggests strong patent protection remaining\n- Biologics typically receive 12 years of exclusivity from approval date\n\n## Market / SoC Snapshot\n- Joins lecanemab (Leqembi) and aducanumab (Aduhelm) as FDA-approved anti-amyloid antibodies\n- Addresses large and growing patient population with early Alzheimer's disease\n- Requires specialized infrastructure for administration and monitoring\n- Potential market differentiation through rapid plaque clearance and treatment discontinuation protocol\n- Requires biomarker confirmation of amyloid pathology prior to treatment\n- APOE genotyping recommended for risk stratification\n\n## Key Risks + Next Actions\n- ARIA risk requires careful patient selection and monitoring protocols\n- Need for MRI monitoring increases healthcare resource utilization\n- Specialized infusion centers and trained personnel required\n- Establish clear protocols for patient selection, monitoring, and treatment discontinuation\n- Develop risk mitigation strategies for ARIA management\n- Implement education programs for healthcare providers and patients\n- Consider real-world evidence collection to assess long-term outcomes\n\n## Evidence Gaps\n- Limited data on long-term efficacy beyond clinical trial duration\n- Lack of direct comparative studies with other anti-amyloid therapies\n- Insufficient data on quality of life and patient-reported outcomes\n- Limited evidence on cost-effectiveness and healthcare resource utilization\n- Optimal treatment duration and discontinuation criteria not fully established\n- Real-world effectiveness in diverse populations not yet demonstrated", "additional_kwargs": {}, "response_metadata": {"id": "msg_015twEXW1F895npEo7GxcJSP", "model": "claude-3-7-sonnet-20250219", "stop_reason": "end_turn", "stop_sequence": null, "usage": {"cache_creation": {"ephemeral_1h_input_tokens": 0, "ephemeral_5m_input_tokens": 0}, "cache_creation_input_tokens": 0, "cache_read_input_tokens": 0, "input_tokens": 7529, "output_tokens": 698, "server_tool_use": null, "service_tier": "standard"}, "model_name": "claude-3-7-sonnet-20250219", "model_provider": "anthropic"}, "type": "ai", "name": null, "id": "lc_run--019b2d13-769c-7823-b6a8-c1686067d492-0", "tool_calls": [], "invalid_tool_calls": [], "usage_metadata": {"input_tokens": 7529, "output_tokens": 698, "total_tokens": 8227, "input_token_details": {"cache_read": 0, "cache_creation": 0, "ephemeral_5m_input_tokens": 0, "ephemeral_1h_input_tokens": 0}}}]}}} 

event: message
data: {"node": "synthesize", "content": "# FINAL DECISION BRIEF: DONANEMAB FOR EARLY ALZHEIMER'S DISEASE\n\n## Executive Recommendation\nRecommend approval for donanemab (Kisunla™) for early Alzheimer's disease based on demonstrated efficacy in slowing clinical progression and favorable benefit-risk profile.\n\n## Scientific Rationale\n- IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β\n- Rapidly reduces amyloid plaque burden in the brain\n- Addresses a key pathological hallmark of Alzheimer's disease\n- Demonstrates disease-modifying potential by targeting underlying pathology\n\n## Clinical Evidence Snapshot\n- FDA approved on July 2, 2023 for early symptomatic Alzheimer's disease\n- TRAILBLAZER-ALZ 2 (Phase 3) showed statistically significant reduction in clinical decline at Week 76\n- Demonstrated improvements on iADRS, ADAS-Cog13, ADCS-iADL, and CDR-SB scales\n- 24% of patients experienced ARIA-E vs. 14% on placebo\n- 31% of patients experienced ARIA-H vs. 13% on placebo\n- Rapid amyloid plaque clearance observed within months of treatment initiation\n- Treatment discontinuation possible after amyloid clearance (typically 12-18 months)\n\n## IP / Exclusivity Quick View\n- Developed by Eli Lilly and Company\n- Marketed under brand name Kisunla™\n- Recent FDA approval (July 2023) suggests strong patent protection remaining\n- Biologics typically receive 12 years of exclusivity from approval date\n\n## Market / SoC Snapshot\n- Joins lecanemab (Leqembi) and aducanumab (Aduhelm) as FDA-approved anti-amyloid antibodies\n- Addresses large and growing patient population with early Alzheimer's disease\n- Requires specialized infrastructure for administration and monitoring\n- Potential market differentiation through rapid plaque clearance and treatment discontinuation protocol\n- Requires biomarker confirmation of amyloid pathology prior to treatment\n- APOE genotyping recommended for risk stratification\n\n## Key Risks + Next Actions\n- ARIA risk requires careful patient selection and monitoring protocols\n- Need for MRI monitoring increases healthcare resource utilization\n- Specialized infusion centers and trained personnel required\n- Establish clear protocols for patient selection, monitoring, and treatment discontinuation\n- Develop risk mitigation strategies for ARIA management\n- Implement education programs for healthcare providers and patients\n- Consider real-world evidence collection to assess long-term outcomes\n\n## Evidence Gaps\n- Limited data on long-term efficacy beyond clinical trial duration\n- Lack of direct comparative studies with other anti-amyloid therapies\n- Insufficient data on quality of life and patient-reported outcomes\n- Limited evidence on cost-effectiveness and healthcare resource utilization\n- Optimal treatment duration and discontinuation criteria not fully established\n- Real-world effectiveness in diverse populations not yet demonstrated"}

event: partial_brief
data: {"node": "synthesize", "decision_brief": "# FINAL DECISION BRIEF: DONANEMAB FOR EARLY ALZHEIMER'S DISEASE\n\n## Executive Recommendation\nRecommend approval for donanemab (Kisunla™) for early Alzheimer's disease based on demonstrated efficacy in slowing clinical progression and favorable benefit-risk profile.\n\n## Scientific Rationale\n- IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β\n- Rapidly reduces amyloid plaque burden in the brain\n- Addresses a key pathological hallmark of Alzheimer's disease\n- Demonstrates disease-modifying potential by targeting underlying pathology\n\n## Clinical Evidence Snapshot\n- FDA approved on July 2, 2023 for early symptomatic Alzheimer's disease\n- TRAILBLAZER-ALZ 2 (Phase 3) showed statistically significant reduction in clinical decline at Week 76\n- Demonstrated improvements on iADRS, ADAS-Cog13, ADCS-iADL, and CDR-SB scales\n- 24% of patients experienced ARIA-E vs. 14% on placebo\n- 31% of patients experienced ARIA-H vs. 13% on placebo\n- Rapid amyloid plaque clearance observed within months of treatment initiation\n- Treatment discontinuation possible after amyloid clearance (typically 12-18 months)\n\n## IP / Exclusivity Quick View\n- Developed by Eli Lilly and Company\n- Marketed under brand name Kisunla™\n- Recent FDA approval (July 2023) suggests strong patent protection remaining\n- Biologics typically receive 12 years of exclusivity from approval date\n\n## Market / SoC Snapshot\n- Joins lecanemab (Leqembi) and aducanumab (Aduhelm) as FDA-approved anti-amyloid antibodies\n- Addresses large and growing patient population with early Alzheimer's disease\n- Requires specialized infrastructure for administration and monitoring\n- Potential market differentiation through rapid plaque clearance and treatment discontinuation protocol\n- Requires biomarker confirmation of amyloid pathology prior to treatment\n- APOE genotyping recommended for risk stratification\n\n## Key Risks + Next Actions\n- ARIA risk requires careful patient selection and monitoring protocols\n- Need for MRI monitoring increases healthcare resource utilization\n- Specialized infusion centers and trained personnel required\n- Establish clear protocols for patient selection, monitoring, and treatment discontinuation\n- Develop risk mitigation strategies for ARIA management\n- Implement education programs for healthcare providers and patients\n- Consider real-world evidence collection to assess long-term outcomes\n\n## Evidence Gaps\n- Limited data on long-term efficacy beyond clinical trial duration\n- Lack of direct comparative studies with other anti-amyloid therapies\n- Insufficient data on quality of life and patient-reported outcomes\n- Limited evidence on cost-effectiveness and healthcare resource utilization\n- Optimal treatment duration and discontinuation criteria not fully established\n- Real-world effectiveness in diverse populations not yet demonstrated\n\n## Citations\n1. https://clinicaltrials.gov/study/NCT05508789\n2. https://www.clinicaltrials.gov/study/NCT04437511\n3. https://clinicaltrials.gov/study/NCT03367403\n4. https://clinicaltrials.gov/study/NCT05738486\n5. https://cdn.clinicaltrials.gov/large-docs/11/NCT04437511/Prot_000.pdf\n6. https://trials.lilly.com/en-US/trial\n7. https://clevelandadrc.org/education-resources/managing-dementia/new-information-regarding-an-fda-approved-treatment-for-alzheimers-disease/\n8. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease\n9. https://www.alzint.org/news-events/news/donanemab-update-new-alzheimers-disease-treatment-approved-by-the-fda/\n10. https://www.nejm.org/doi/full/10.1056/NEJMoa2100708\n11. https://jamanetwork.com/journals/jama/fullarticle/2807533\n12. https://www.sciencedirect.com/science/article/pii/S2274580725000949\n13. https://pmc.ncbi.nlm.nih.gov/articles/PMC12040886/\n14. https://dig.pharmacy.uic.edu/faqs/2024-2/sep-2024-faqs/what-evidence-supports-the-efficacy-and-safety-of-donanemab-for-alzheimer-disease/\n15. https://www.neurologylive.com/view/donanemab-for-treatment-of-alzheimer-s-disease"}

event: final
data: {"session_id": "demo1", "decision_brief": "# FINAL DECISION BRIEF: DONANEMAB FOR EARLY ALZHEIMER'S DISEASE\n\n## Executive Recommendation\nRecommend approval of donanemab (Kisunla) for early Alzheimer's disease based on demonstrated efficacy in slowing cognitive decline and significant amyloid plaque clearance.\n\n## Scientific Rationale\n- Monoclonal antibody that selectively targets pyroglutamate Aβ at position 3 (N3pG amyloid plaques)\n- Facilitates amyloid plaque removal through microglial-mediated phagocytosis\n- Addresses core pathology of Alzheimer's disease according to the amyloid hypothesis\n- Demonstrates dose-dependent reduction in brain amyloid burden\n\n## Clinical Evidence Snapshot\n- FDA approved on July 2, 2024 for mild cognitive impairment or mild dementia due to Alzheimer's disease\n- TRAILBLAZER-ALZ Phase 3 trial (NCT04437511) showed statistically significant reduction in clinical decline:\n  * 28.9% slowing of cognitive decline vs. placebo at 76 weeks\n  * Significant improvement on iADRS (2.92 points, p<0.0001)\n  * Improvements on ADAS-Cog13 (-1.33, p=0.0006) and ADCS-iADL (1.70, p=0.0001)\n  * CDR-SB improvement (-0.70, p<0.0001)\n- Complete amyloid clearance observed in subset of patients\n- Most effective in early disease stages (mild cognitive impairment/mild dementia)\n\n## IP / Exclusivity Quick View\n- Developed by Eli Lilly and Company\n- Brand name: Kisunla (donanemab-azbt)\n- Recently approved (July 2024), suggesting substantial remaining patent protection\n- Biological product with 12 years of exclusivity from approval date\n\n## Market / SoC Snapshot\n- Joins emerging class of anti-amyloid monoclonal antibodies for Alzheimer's disease\n- Competes with lecanemab (Leqembi) and aducanumab (Aduhelm)\n- Medicare coverage available for patients enrolled in CMS-approved registry\n- Addresses significant unmet need in early Alzheimer's disease population\n- Potential market of millions with early-stage Alzheimer's disease in US alone\n\n## Key Risks + Next Actions\n- ARIA (Amyloid-Related Imaging Abnormalities) risk requires monitoring\n- Limited data on long-term safety beyond clinical trial duration\n- Specialized administration and monitoring requirements may limit access\n- High cost likely based on similar biologics in this class\n- Next actions:\n  * Develop risk mitigation strategy for ARIA and other adverse events\n  * Establish post-marketing surveillance program\n  * Determine optimal treatment duration guidelines\n  * Develop patient selection criteria to maximize benefit/risk ratio\n\n## Evidence Gaps\n- Long-term efficacy and safety beyond clinical trial duration\n- Comparative effectiveness versus other anti-amyloid therapies\n- Optimal treatment duration and discontinuation criteria after amyloid clearance\n- Biomarker or genetic predictors of treatment response\n- Real-world effectiveness in diverse populations\n- Cost-effectiveness and healthcare system impact\n- Effects in moderate-to-severe disease stages\n\n## Citations\n1. https://clinicaltrials.gov/study/NCT05508789\n2. https://www.clinicaltrials.gov/study/NCT04437511\n3. https://clinicaltrials.gov/study/NCT03367403\n4. https://clinicaltrials.gov/study/NCT05738486\n5. https://cdn.clinicaltrials.gov/large-docs/11/NCT04437511/Prot_000.pdf\n6. https://trials.lilly.com/en-US/trial\n7. https://eastonad.ucla.edu/patient-care/alzheimers-disease-treatments/donanemab\n8. https://www.butler.org/memoryandaging/fda-approves-donanemab-for-early-alzheimers-disease-treatment\n9. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease\n10. https://www.alzint.org/news-events/news/donanemab-update-new-alzheimers-disease-treatment-approved-by-the-fda/\n11. https://jamanetwork.com/journals/jama/fullarticle/2807533\n12. https://www.emjreviews.com/neurology/news/donanemab-trial-offers-hope-for-alzheimers-treatment/\n13. https://www.neurologyadvisor.com/news/donanemab-induces-amyloid-clearance-early-alzheimer-disease/\n14. https://onlinelibrary.wiley.com/doi/full/10.1002/cdt3.155\n15. https://pmc.ncbi.nlm.nih.gov/articles/PMC11859624/\n16. https://go.drugbank.com/drugs/DB16647", "citations": ["https://clinicaltrials.gov/study/NCT05508789", "https://www.clinicaltrials.gov/study/NCT04437511", "https://clinicaltrials.gov/study/NCT03367403", "https://clinicaltrials.gov/study/NCT05738486", "https://cdn.clinicaltrials.gov/large-docs/11/NCT04437511/Prot_000.pdf", "https://trials.lilly.com/en-US/trial", "https://eastonad.ucla.edu/patient-care/alzheimers-disease-treatments/donanemab", "https://www.butler.org/memoryandaging/fda-approves-donanemab-for-early-alzheimers-disease-treatment", "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease", "https://www.alzint.org/news-events/news/donanemab-update-new-alzheimers-disease-treatment-approved-by-the-fda/", "https://jamanetwork.com/journals/jama/fullarticle/2807533", "https://www.emjreviews.com/neurology/news/donanemab-trial-offers-hope-for-alzheimers-treatment/", "https://www.neurologyadvisor.com/news/donanemab-induces-amyloid-clearance-early-alzheimer-disease/", "https://onlinelibrary.wiley.com/doi/full/10.1002/cdt3.155", "https://pmc.ncbi.nlm.nih.gov/articles/PMC11859624/", "https://go.drugbank.com/drugs/DB16647"], "confidence_score": null, "metadata": {"has_prior_messages": false}}

event: done
data: {"ok": true}
